Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

BACKGROUND: We assessed the safety profile of lasmiditan, a selective 5-HT(1F) receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. METHODS: SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cephalalgia
Asıl Yazarlar: Krege, John H, Rizzoli, Paul B, Liffick, Emily, Doty, Erin G, Dowsett, Sherie A, Wang, Jianing, Buchanan, Andrew S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6787764/
https://ncbi.nlm.nih.gov/pubmed/31166697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102419855080
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller